Gantenerumab for the treatment of Alzheimer's disease

Expert Opinion on Biological Therapy
Julien DelrieuBruno Vellas

Abstract

Alzheimer's disease is the leading cause of dementia in the elderly, and there is no disease-modifying therapy yet available. Immunotherapy directed against the β-amyloid peptide may be capable of slowing the rate of disease progression. Gantenerumab is the first fully human anti-β-amyloid monoclonal antibody. To review the efficacy and safety of immunotherapy drugs and in particular gantenerumab, we used the database MEDLINE. The primary literature on gantenerumab is reviewed in its entirety. We also reviewed the English-language, pre-clinical and clinical trials designed to evaluate the efficacy or/and safety of immunotherapy drugs, from 1999 through 2011. Other Alzheimer's disease-passive immunotherapeutics currently in development, according to www.clinicaltrials.gov, are also discussed. Gantenerumab appears capable of reducing the cerebral β-amyloid peptide burden in patients with Alzheimer's disease. Its ability to slow disease progression remains uncertain because no clinical data are available at present. The next step will be to investigate whether removal of brain amyloid translates into clinical benefit for patients at doses of gantenerumab that reduce brain amyloid and are well tolerated.

References

Feb 22, 2001·Free Radical Biology & Medicine·C A RottkampM A Smith
Jan 2, 2003·Nature Reviews. Drug Discovery·Ole Henrik Brekke, Inger Sandlie
May 11, 2005·Neurology·S GilmanUNKNOWN AN1792(QS-21)-201 Study Team
Feb 14, 2006·Current Alzheimer Research·Hyoung-gon LeeMark A Smith
May 24, 2006·Acta Neuropathologica·Rudy J CastellaniMark A Smith
Aug 18, 2006·Journal of Alzheimer's Disease : JAD·Dave Morgan
Jan 19, 2007·The Journal of Pharmacology and Experimental Therapeutics·Hyoung-gon LeeMark A Smith
Oct 30, 2007·Free Radical Biology & Medicine·Takaaki HayashiMasao Nakamura
Jun 4, 2008·Journal of Neuropathology and Experimental Neurology·Rudy J CastellaniMark A Smith
Jul 4, 2008·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Sally SchroeterDora Games
Oct 28, 2008·Brain : a Journal of Neurology·D BocheJ A R Nicoll
Dec 26, 2008·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Jessica Koenigsknecht-TalbooDavid M Holtzman
Mar 12, 2009·CNS & Neurological Disorders Drug Targets·Donna M Wilcock, Carol A Colton
Nov 20, 2009·Neurology·S SallowayUNKNOWN Bapineuzumab 201 Clinical Trial Investigators
Dec 25, 2009·Rinshō shinkeigaku = Clinical neurology·Takeshi Tabira
Jan 20, 2010·Lancet Neurology·Clifford R JackJohn Q Trojanowski
Mar 23, 2010·The Journal of Nutrition, Health & Aging·P S Aisen
Mar 23, 2010·The Journal of Nutrition, Health & Aging·J M CedarbaumM Grundman
May 26, 2010·Expert Opinion on Biological Therapy·Geoffrey A Kerchner, Adam L Boxer
May 28, 2010·Alzheimer Disease and Associated Disorders·Ronald S BlackMichael Grundman
Jan 26, 2011·Expert Opinion on Biological Therapy·Refik PulMartin Stangel
Apr 21, 2011·Expert Opinion on Biological Therapy·Hossein Samadi, David Sultzer
Jun 24, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Christoph WiessnerMatthias Staufenbiel
Jul 26, 2011·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Reisa A SperlingRachel J Schindler
Oct 12, 2011·Archives of Neurology·Susanne OstrowitzkiLuca Santarelli
Nov 30, 2011·Journal of Neurochemistry·Megan E Larson, Sylvain E Lesné

❮ Previous
Next ❯

Citations

Aug 15, 2013·Drugs & Aging·Camryn Berk, Marwan N Sabbagh
Jun 27, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Kaj BlennowHenrik Zetterberg
Oct 23, 2012·Alzheimer's Research & Therapy·Hugo VandersticheleAndreas Jeromin
Nov 13, 2013·Alzheimer's Research & Therapy·Niels D Prins, Philip Scheltens
Aug 10, 2013·Expert Review of Clinical Pharmacology·Gabriel C Léger, Fadi Massoud
Jul 2, 2014·Expert Opinion on Biological Therapy·Francesco PanzaGiancarlo Logroscino
May 7, 2013·The Medical Clinics of North America·Jagan A Pillai, Jeffrey L Cummings
Aug 2, 2014·Expert Review of Neurotherapeutics·Francesco PanzaGiancarlo Logroscino
Feb 15, 2014·Human Vaccines & Immunotherapeutics·Hayk DavtyanMichael G Agadjanyan
Jan 31, 2019·International Journal of Molecular Sciences·Yuan DongLin Hou
Jan 22, 2014·Current Opinion in Psychiatry·Francesco PanzaVincenzo Solfrizzi
Feb 5, 2014·Expert Review of Clinical Immunology·Francesco PanzaGiancarlo Logroscino
Nov 18, 2018·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Christel ClaesCatherine M Verfaillie
Jan 4, 2018·Annals of Clinical and Translational Neurology·Jia-Jie MoJin-Shan Feng
Sep 15, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Max HolzerAndreas Hilgeroth
Dec 8, 2019·Metabolic Brain Disease·Yong Qi LeongRhun Yian Koh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Related Papers

Expert Opinion on Biological Therapy
Hossein Samadi, David Sultzer
Expert Review of Clinical Immunology
Bruno P ImbimboFrancesco Panza
Expert Opinion on Biological Therapy
Geoffrey A Kerchner, Adam L Boxer
© 2021 Meta ULC. All rights reserved